Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of light therapy for the treatment of bipolar type II patients relapsing into a depressive phase during autumn or winter.


Clinical Trial Description

Bipolar type II depression is a very frequent condition for which we still have a significant lack of acute treatments. There is now consistent evidence that light-therapy treatment produced a significant decrease of depressive symptoms for seasonal and non-seasonal unipolar depression. But there are no long-term studies of light therapy for the treatment of non-seasonal unipolar depression. It is also important to note that many of these studies involved co-therapy with antidepressant drugs or sleep-deprivation, making the interpretation of the results even more difficult. Therefore, we propose to study the efficacy and safety of light therapy for the treatment of bipolar type II patients relapsing into a depressive phase during the period of September to mid-March. This will be a double-blind randomized placebo-controlled study. Bipolar II out-patients will be recruited from our bipolar disorders program and from our 5 general psychiatry out-patient clinics. We will recruit bipolar type II patients facing a depressive phase and after they give their informed consent and we had verified they meet all inclusion and exclusion criteria, they will be randomized blindly to Bright-light (10 000 lux) vs Dim-light placebo (100 lux) therapies. Both, patient and investigator/rater will be blind to the type of light treatment assigned to the patient. The light therapy will take place during 30 minutes daily in the morning AFTER the usual awakening time of the patient in order to avoid even partial sleep deprivation which would confound the results if we were to observe a greater switch rate into mania or hypomania. Reasons for study termination can be serious side-effects, development of suicidal ideations or hypomanic/manic symptoms, patient's own decision, or any other of the exclusion criteria being fulfilled during the course of the study. Depressive and manic/hypomanic symptoms, quality of life, sleep quality and side-effects will be assessed at baseline and during the study. Biological parameters will also be measured along the study. We think that this study will allow us to determine the efficacy and safety of a 5 weeks bright light therapy for Bipolar type II depression and provide open label data as to the long term benefits of this treatment if prolonged over 5 weeks during the "dark" months of the year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00590265
Study type Interventional
Source Douglas Mental Health University Institute
Contact
Status Active, not recruiting
Phase N/A
Start date January 2008
Completion date June 2025

See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Recruiting NCT02919280 - Dallas 2K: A Natural History Study of Depression
Completed NCT00060489 - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression Phase 3
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT04057378 - Optimal Electrical Stimulus During Electroconvulsive Therapy Phase 4
Completed NCT03287037 - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression N/A
Completed NCT00483548 - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression Phase 3
Not yet recruiting NCT05568823 - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder N/A
Completed NCT00191399 - Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response Phase 4
Recruiting NCT05436613 - Transcranial Direct Current Stimulation Therapy for Bipolar Depression N/A
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Withdrawn NCT02625779 - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression Phase 2
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting NCT02778256 - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder N/A
Active, not recruiting NCT04643210 - Management of my Bipolarity Intervention in Bipolar Disorder Patients N/A
Completed NCT01396447 - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression Phase 2
Enrolling by invitation NCT02827045 - Study of a Vestibular Biomarker of Phase in Bipolar Disorder